Results For "Kotak-Alternate-Asset-Managers-Limited"

1 News Found

Kotak Alts invests Rs. 200 million in Cellogen Therapeutics

Biopharma | May 18, 2026

Kotak Alts invests Rs. 200 million in Cellogen Therapeutics

Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities

Latest Stories

Lupin launches Atharv ability neuro-rehabilitation centre in Delhi

Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%

Amrutanjan Healthcare expands portfolio in pain management

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare

Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare

Dr Vidya Veldore Vice President, Clinical Operations, 4baseCare

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

Dushyant Sapre Founder and CEO, SwishX

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Agentic AI poised to reshape pharma operations beyond pilot-stage adoption: Duraisamy Rajan Palani, Founder & CEO, Archimedis Digital

Duraisamy Rajan Palani Founder and CEO, Archimedis Digital

Packaging